The aim of the project is to develop an innovative platform for screaning, design and production of bispecific biotechnology therapists in the treatment of inflammatory diseases, based on Phage Display technology and an innovative expression system. Bispecific constructions are currently one of the most innovative trends in the development of therapy. This approach allows for the design of molecules capable of simultaneously inhibiting/modulating two molecular targets, enabling synergistic action of both therapeutic elements and increasing the effectiveness of therapy and patient safety. The project will result in the development and evaluation during clinical trials of an innovative biotechnology product used in the treatment of inflammatory diseases, such as: rheumatoid arthritis, psoriasis or non-specific colitis including Crohn’s disease and ulcerative colitis. These diseases are a huge problem of civilisation, which very often affects low-income people. Implementation of the project results will lead to lowering the price of the latest generation of therapists, increasing their availability and thus reducing the socio-economic costs associated with these diseases. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article: 25 EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014).